UroGen Pharma Ltd — Quarterly Financial Statistics (NASDAQ:URGN) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -13.62 M-42.02 M-39.83 M-42.27 M-38.33 M -162.44 M Cash from investing activities 60.62 M-25.96 M28.41 M31.4 M27.72 M 61.56 M Cash from financing activities 71 K34 K296 K8.27 M31.32 M 39.92 M Free cash flow -13.73 M-42.07 M-39.97 M-42.36 M-38.34 M -162.73 M

News

UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers

UroGen Pharma at TD Cowen Conference: Strategic Growth and Innovation

Oppenheimer raises UroGen Pharma stock price target to $34 on Zusduri sales

Oppenheimer reiterates UroGen Pharma stock rating on strong Zusduri sales

Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts

Palantir and AeroVironment among market cap stock movers on Monday

Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates

UroGen Pharma earnings missed by $0.06, revenue fell short of estimates

UroGen reports $15.8M in ZUSDURI sales, refinances debt

UroGen refinances debt with $250M facility at 8.25% rate

UroGen faces earnings test as ZUSDURI launch ramps

UroGen Pharma CMO Schoenberg sells $145k in shares